Extending ImmunoSpot® Assays’ Sensitivity for Detecting Rare Antigen-Specific B Cells to One in a Million—And Possibly Lower

<b>Background/Objectives</b>: Despite clonal expansion during a primary immune response, or after subsequent antigen encounters, the frequency of memory B cells (B<sub>mem</sub>) specific for an antigen remains low, making their detection difficult. However, unlike serum antibodies, which have a short half-life in vivo and thus require continuous replenishment to maintain stable titers, circulating B<sub>mem</sub> are long-lived; they preserve immunological preparedness through their ability to rapidly engage in recall responses and differentiate into antibody-secreting cells (ASCs) upon antigen encounter. To this end, development of assays suited for the reliable detection of rare antigen-specific B<sub>mem</sub> is critical and can provide insights into an individual's antigen exposure history and immune status beyond that offered by traditional serum antibody measurements alone. <b>Methods</b>: ImmunoSpot<sup>®</sup> has emerged as a suitable technique for the detection of individual antigen-specific B cells through visualizing their antibody-derived secretory footprints. Here, we report the theoretical and practical foundations for detecting rare antigen-specific B<sub>mem</sub> in human peripheral blood mononuclear cells (PBMC). Leveraging the unique availability of verifiably naïve vs. antigen-experienced human samples, we used SARS-CoV-2 Spike (S-) and Nucleocapsid (NCAP) antigens to interrogate the presence of B<sub>mem</sub> with these respective specificities. <b>Results</b>: While 100% diagnostic accuracy was achieved for both antigens, detection of NCAP-specific B<sub>mem</sub> required reducing the lower detection limit of the standard assay. Specifically, this was achieved by testing a total of 2 million PBMC across multiple replicate assay wells and assessing the cumulative number of secretory footprints detected. <b>Conclusion</b>: The protocols described here should facilitate the reliable detection of ASCs present at varying precursor frequencies and serve as guidance for routine immune monitoring of rare B<sub>mem</sub> with specificity for any antigen.

Authors

Publication Details

Journal
Vaccines
Published
2026-01-15
DOI
https://doi.org/10.3390/vaccines14010088
Citations
1
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
31.92
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Extending ImmunoSpot® Assays’ Sensitivity for Detecting Rare Antigen-Specific B Cells to One in a Million—And Possibly Lower

Alexey Y. Karulin, Greg A. Kirchenbaum, Noémi Becza, Paul Lehmann et al.
1 citations
Vaccines
Monoclonal and Polyclonal Antibodies Research
31.92
article

Extending ImmunoSpot® Assays’ Sensitivity for Detecting Rare Antigen-Specific B Cells to One in a Million—And Possibly Lower

Alexey Y. Karulin, Greg A. Kirchenbaum, Noémi Becza, Paul Lehmann, Lingling Yao
article en
1 citations

Abstract

<b>Background/Objectives</b>: Despite clonal expansion during a primary immune response, or after subsequent antigen encounters, the frequency of memory B cells (B<sub>mem</sub>) specific for an antigen remains low, making their detection difficult. However, unlike serum antibodies, which have a short half-life in vivo and thus require continuous replenishment to maintain stable titers, circulating B<sub>mem</sub> are long-lived; they preserve immunological preparedness through their ability to rapidly engage in recall responses and differentiate into antibody-secreting cells (ASCs) upon antigen encounter. To this end, development of assays suited for the reliable detection of rare antigen-specific B<sub>mem</sub> is critical and can provide insights into an individual's antigen exposure history and immune status beyond that offered by traditional serum antibody measurements alone. <b>Methods</b>: ImmunoSpot<sup>®</sup> has emerged as a suitable technique for the detection of individual antigen-specific B cells through visualizing their antibody-derived secretory footprints. Here, we report the theoretical and practical foundations for detecting rare antigen-specific B<sub>mem</sub> in human peripheral blood mononuclear cells (PBMC). Leveraging the unique availability of verifiably naïve vs. antigen-experienced human samples, we used SARS-CoV-2 Spike (S-) and Nucleocapsid (NCAP) antigens to interrogate the presence of B<sub>mem</sub> with these respective specificities. <b>Results</b>: While 100% diagnostic accuracy was achieved for both antigens, detection of NCAP-specific B<sub>mem</sub> required reducing the lower detection limit of the standard assay. Specifically, this was achieved by testing a total of 2 million PBMC across multiple replicate assay wells and assessing the cumulative number of secretory footprints detected. <b>Conclusion</b>: The protocols described here should facilitate the reliable detection of ASCs present at varying precursor frequencies and serve as guidance for routine immune monitoring of rare B<sub>mem</sub> with specificity for any antigen.

VaccinesVol. 14(1)
Openalex Percentile: Top 2%
Monoclonal and Polyclonal Antibodies Research
31.92
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Extending ImmunoSpot® Assays’ Sensitivity for Detecting Rare Antigen-Specific B Cells to One in a Million—And Possibly Lower — Alexey Y. Karulin, Greg A. Kirchenbaum, et al. · Vaccines (2026) | TGRS Research Map | TGRS